Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock
Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).
Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock
Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).
Enliven Therapeutics Director J. Scott Garland Sells $607K of Stock
J. Scott Garland, Director, sold 13,000 shares of Enliven Therapeutics, Inc. at $46.67 a share, worth $607K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).
Enliven Therapeutics CFO Benjamin Hohl Sells $303K of Stock
Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $50.03 to $51.49 a share (average $50.35) in 3 transactions, worth $303K in total on Sep 17, 2026. Shares held after the trade: 38,000 (-0.8%).
Enliven Therapeutics CMO Helen Louise Collins Sells $252K of Stock
Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $50.03 to $51.48 a share (average $50.35) in 3 transactions, worth $252K in total on Sep 17, 2026. Shares held after the trade: 25,000 (-1.0%).